- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00403143
Do Blue-Blocking Lenses Block Blue Colour From Our Lives?
Do Blue-Blocking Lenses Block Colour From Our Lives? A Randomised Controlled Study Measuring Colour Vision Using the Gold Standard Colour Vision Test (an Anomaloscope)in Patients With Blue Light Filtering Intraocular Lenses (Tinted Yellow) and Comparing This With Patients Inserted With Clear, Non Blue Light Filtering Intraocular Lenses During Cataract Surgery
Panoramica dello studio
Descrizione dettagliata
As we all age, the natural lens inside our eyes becomes denser, hazy and more yellow in colour. In other words, cataracts develop. In order to enable clear vision again, cataract surgery is performed. This involves removing the natural lens from the eye and replacing it with a synthetic lens implant inside the eye. Cataract surgery with insertion of a lens implant was first done in 1948 but didn't become routine until the early 1980s. Around this time, awareness about the harmful effects of UV light were raised and by 1986, lens implants routinely had a UV filter incorporated into them.1 As early as 1992, a study examining patients who had had a high occupational exposure to blue and visible light, concluded that there is a positive association between long term exposure to visible light and age related wear and tear change at the back of the eye, termed age related macular degeneration (AMD).2 This theory was supported by several studies which have reported an increased rate of progression of AMD in patients after cataract surgery with a clear lens implant (It is known that clear lens implants transmit more blue light to the back of the eye compared with the natural aging lens).3 Laboratory studies in 2000 showed that blue light causes damage to aging retinal cells (the nerve cells at the back of the eye which are important in enabling us to see), more so than green light or white light.4 Experimental studies with rats also showed that exposure to blue light was 30 times more damaging to retinal cells compared with yellow light.5 A further laboratory study in 2004 confirmed that by protecting aging retinal cells with a blue light filtering lens, damage caused by blue light is prevented.6 Yellow tinted, blue light filtering lens implants have been in production since 1991, first by Hoya in Tokyo and now by Alcon as well. Alcon produce the Acrysof Natural lens implant which has been designed to mimic the 53 year old natural lens and which received FDA and CE approval in 2003. To date, over 2 million of these lenses have been implanted in patients world wide.7 Although these lens implants are sometimes used in patients having cataract surgery in the UK, this is not yet routine. One of the concerns about them is whether or not they limit colour vision in any way. There have been some studies examining this and so far, none of them have found a statistically significant difference in the colour vision between patients with non-tinted lens implants and blue-filtering lens implants.8,9,10 However, none of the studies thus far, have employed colour vision testing with an anomaloscope (which is considered to be the gold standard colour vision test).11 In addition, none of them have taken into account the level of capsular opacification (the capsule is a cling film bag-like structure that supports the lens implant inside the eye and can over a period of time, become thickened and hazy following cataract surgery) and the level of macular pigment (yellow pigment which we have on the centre part of the back of our eyes which is thought to contribute towards filtering blue light) in patients' eyes.
Age related macular degeneration is already the commonest cause of blindness in the UK. It is a growing problem, particularly with our aging population and increasing levels of ambient light which we are exposed to in our daily lives. Although the evidence is strongly in favour of filtering blue light and the need for protective measures against AMD are pressing, we need to be satisfied that there are no adverse effects of blocking blue from our lives.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Amynah Goawalla, BSc, MBBS MRCOphth
- Numero di telefono: 7130 020 963
- Email: amynahgoawalla@nwlh.nhs.uk
Luoghi di studio
-
-
-
London, Regno Unito, NW10 7NS
- Reclutamento
- North West London Hospitals NHS Trust
-
Contatto:
- Iva Hauptmannova, BSc MA
- Numero di telefono: 5286 020 8869
- Email: iva.hauptmannova@nwlh.nhs.uk
-
Investigatore principale:
- Gillian Vafidis, MA FRCS FRCOphth
-
Sub-investigatore:
- Amynah Goawalla, BSc MBBS MRCOphth
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- patients who have had uncomplicated cataract surgery in one eye and have a cataract in the other eye
- patients who are over 18 years of age
- patients who are fully able to independently give consent to have surgery
Exclusion Criteria:
- patients who have any other ocular co-morbidity that may account for reduction in vision in either eye (as this may confound the condition)
- patients who are colour blind
- patients who suffered previous post-operative complications
- patients under 18
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
---|
To objectively determine whether colour vision is reduced with a blue-light filtering
|
intraocular lens compared with a colourless intraocular implant in cataract surgery
|
Misure di risultato secondarie
Misura del risultato |
---|
To determine whether patients subjectively are able to tell whether they have been
|
implanted with yellow tinted intraocular lens during their cataract surgery or colourless one
|
Collaboratori e investigatori
Investigatori
- Direttore dello studio: Gillian Vafidis, MA FRCS FRCOphth, London North West Healthcare NHS Trust
Studiare le date dei record
Studia le date principali
Inizio studio
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 06/Opa/23
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su intervento di cataratta
-
Alcon, a Novartis CompanyTerminato
-
ARCAGY/ GINECO GROUPReclutamentoCancro ovarico stadio IIIC | Stadio del cancro ovarico IV | Cancro ovarico stadio IIIbFrancia
-
Mayo ClinicTerminatoReflusso gastroesofageo | Ernia, iatale | Sondaggi e questionari | FundoplicatioStati Uniti
-
Fudan UniversitySconosciuto
-
AGO Study GroupCancer Research UK; ARCAGY/ GINECO GROUP; Grupo Español de Investigación en Cáncer... e altri collaboratoriCompletatoCancro ovarico | Cancro della tuba di Falloppio | Cancro della cavità peritonealeSpagna, Francia, Danimarca, Belgio, Germania, Austria, Cina, Italia, Corea, Repubblica di, Norvegia, Svezia, Regno Unito
-
Dr. Faruk SemizIscrizione su invito
-
National Cancer Centre, SingaporeCompletatoMalattie della tiroideSingapore
-
University of TriesteCompletato
-
Kocaeli Derince Education and Research HospitalKocaeli UniversitySconosciutoMiglioramento del recupero dopo l'intervento chirurgico | Chirurgia a cuore apertoTacchino
-
Assiut UniversityNon ancora reclutamentoMalattie esofagee | Complicanza di esofagostomia